Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17598007rdf:typepubmed:Citationlld:pubmed
pubmed-article:17598007lifeskim:mentionsumls-concept:C0005775lld:lifeskim
pubmed-article:17598007lifeskim:mentionsumls-concept:C0538161lld:lifeskim
pubmed-article:17598007lifeskim:mentionsumls-concept:C0019134lld:lifeskim
pubmed-article:17598007lifeskim:mentionsumls-concept:C0300926lld:lifeskim
pubmed-article:17598007lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:17598007pubmed:issue1lld:pubmed
pubmed-article:17598007pubmed:dateCreated2007-6-28lld:pubmed
pubmed-article:17598007pubmed:abstractTextHeparin treatment may induce osteoporosis by an unknown mechanism. Osteoprotegerin (OPG), a glycoprotein with a heparin-binding site, is a decoy receptor for RANKL which is responsible for osteoclast development. The objective was to investigate the effect of unfractionated heparin (UFH) and lowmolecular-weight heparin (LMWH; dalteparin) on plasma levels of OPG. Twenty-two male students were allocated to the following treatment regimens; A) one bolus of 5,000 IU UFH iv followed by infusion of 450 IU/kg/24 h for 72 hours (n = 7), B) sc administration of LMWH (200 IU/kg) once daily for 72 hours (n = 8), C) sc administration of 100 IU/kg LMWH once (n = 8), D) sc administration of 250 IU/kg UFH once (n = 7), E) control infusion of saline for 12 hours (n = 7). UFH boluses of 5,000 IU were given 4 and 24 hours after cessation of regimens A and B. Bolus injection of UFH iv caused a prompt increase in plasma OPG from 0.68 ng/ml (SD = 0.09) to 1.13 ng/ml (SD = 0.30) (p = 0.003) which declined during the continuous UFH infusion and reached baseline values after 8 hours (regime A). Similar increases in plasma OPG was obtained by repeated UFH boluses after cessation of treatment. Subcutaneous administration of LMWH (200 IU/kg) caused a modest, but significant (p = 0.002) increase in plasma OPG similar to the mobilization by 250 IU/kg UFH sc, but the LMWH treatment caused a three-fold higher anti-Xa activity (p < 0.001). We conclude that UFH causes a more pronounced vascular mobilization of OPG than LMWH, indicating that UFH has a higher affinity for OPG than LMWH.lld:pubmed
pubmed-article:17598007pubmed:languageenglld:pubmed
pubmed-article:17598007pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17598007pubmed:citationSubsetIMlld:pubmed
pubmed-article:17598007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17598007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17598007pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17598007pubmed:statusMEDLINElld:pubmed
pubmed-article:17598007pubmed:monthJullld:pubmed
pubmed-article:17598007pubmed:issn0340-6245lld:pubmed
pubmed-article:17598007pubmed:authorpubmed-author:VikAndersAlld:pubmed
pubmed-article:17598007pubmed:authorpubmed-author:Sveinbjørnsso...lld:pubmed
pubmed-article:17598007pubmed:authorpubmed-author:HansenJohn-Bj...lld:pubmed
pubmed-article:17598007pubmed:authorpubmed-author:BrodinEllenElld:pubmed
pubmed-article:17598007pubmed:issnTypePrintlld:pubmed
pubmed-article:17598007pubmed:volume98lld:pubmed
pubmed-article:17598007pubmed:ownerNLMlld:pubmed
pubmed-article:17598007pubmed:authorsCompleteYlld:pubmed
pubmed-article:17598007pubmed:pagination148-54lld:pubmed
pubmed-article:17598007pubmed:meshHeadingpubmed-meshheading:17598007...lld:pubmed
pubmed-article:17598007pubmed:meshHeadingpubmed-meshheading:17598007...lld:pubmed
pubmed-article:17598007pubmed:meshHeadingpubmed-meshheading:17598007...lld:pubmed
pubmed-article:17598007pubmed:meshHeadingpubmed-meshheading:17598007...lld:pubmed
pubmed-article:17598007pubmed:meshHeadingpubmed-meshheading:17598007...lld:pubmed
pubmed-article:17598007pubmed:meshHeadingpubmed-meshheading:17598007...lld:pubmed
pubmed-article:17598007pubmed:meshHeadingpubmed-meshheading:17598007...lld:pubmed
pubmed-article:17598007pubmed:meshHeadingpubmed-meshheading:17598007...lld:pubmed
pubmed-article:17598007pubmed:meshHeadingpubmed-meshheading:17598007...lld:pubmed
pubmed-article:17598007pubmed:meshHeadingpubmed-meshheading:17598007...lld:pubmed
pubmed-article:17598007pubmed:year2007lld:pubmed
pubmed-article:17598007pubmed:articleTitleHeparin induces mobilization of osteoprotegerin into the circulation.lld:pubmed
pubmed-article:17598007pubmed:affiliationCenter for Atherothrombotic Research in Tromsø (CART), Department of Medicine, Institute of Clinical Medicine, University of Tromsø, N-9037 Tromsø, Norway. anders.vik@fagmed.uit.nolld:pubmed
pubmed-article:17598007pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17598007pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:17598007pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:4982entrezgene:pubmedpubmed-article:17598007lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17598007lld:entrezgene